TrialBreast cancer research : BCR2026

Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study.

La Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.